title: Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
abstract: Based on ibrutinib pharmacokinetics and potential sensitivity towards CYP3A4-mediated drug-drug interactions (DDIs), a physiologically based pharmacokinetic approach was developed to mechanistically describe DDI with various CYP3A4 perpetrators in healthy men under fasting conditions. These models were verified using clinical data for ketoconazole (strong CYP3A4 inhibitor) and used to prospectively predict and confirm the inducing effect of rifampin (strong CYP3A4 inducer); DDIs with mild (fluvoxamine, azithromycin) and moderate inhibitors (diltiazem, voriconazole, clarithromycin, itraconazole, erythromycin), and moderate (efavirenz) and strong CYP3A4 inducers (carbamazepine), were also predicted. Ketoconazole increased ibrutinib area under the curve (AUC) by 24-fold, while rifampin decreased ibrutinib AUC by 10-fold; coadministration of ibrutinib with strong inhibitors or inducers should be avoided. The ibrutinib dose should be reduced to 140 mg (quarter of maximal prescribed dose) when coadministered with moderate CYP3A4 inhibitors so that exposures remain within observed ranges at therapeutic doses. Thus, dose recommendations for CYP3A4 perpetrator use during ibrutinib treatment were developed and approved for labeling.
authors.affiliation: Janssen Research & Development, Beerse, Belgium. ldzwart@its.jnj.com.
authors.forename: L
authors.initials: L
authors.lastname: de Zwart
authors.affiliation: Janssen Research & Development, Beerse, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Snoeys
authors.affiliation: Janssen Research & Development, San Diego, California, USA.
authors.forename: J
authors.initials: J
authors.lastname: De Jong
authors.affiliation: Pharmacyclics, Inc, Sunnyvale, California, USA.
authors.forename: J
authors.initials: J
authors.lastname: Sukbuntherng
authors.affiliation: Janssen Research & Development, Beerse, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: Mannaert
authors.affiliation: Janssen Research & Development, Beerse, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Monshouwer
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000480:Alkynes; D017963:Azithromycin / Q000494:pharmacology; D048588:Benzoxazines / Q000494:pharmacology; D002220:Carbamazepine / Q000494:pharmacology; D003521:Cyclopropanes; D065701:Cytochrome P-450 CYP3A Inducers / Q000494:pharmacology*; D065692:Cytochrome P-450 CYP3A Inhibitors / Q000494:pharmacology*; D054796:Drug Dosage Calculations; D004347:Drug Interactions; D016666:Fluvoxamine; D006801:Humans; D007654:Ketoconazole / Q000494:pharmacology; D008297:Male; D008954:Models, Biological; D010880:Piperidines; D011720:Pyrazoles / Q000097:blood / Q000493:pharmacokinetics*; D011743:Pyrimidines / Q000097:blood / Q000493:pharmacokinetics*; D012293:Rifampin / Q000494:pharmacology
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D065701:Cytochrome P-450 CYP3A Inducers; D065692:Cytochrome P-450 CYP3A Inhibitors; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D002220:Carbamazepine; D017963:Azithromycin; D000225:Adenine; C098320:efavirenz; D016666:Fluvoxamine; D007654:Ketoconazole; D012293:Rifampin